Biologic therapies and systemic bone loss in rheumatoid arthritis

Dequeker, 1995, Osteoporosis in rheumatoid arthritis, Clin Exp Rheumatol, 13, S21 Green, 2001, Bone changes in early rheumatoid arthritis, Best Pract Res Clin Rheumatol, 15, 105, 10.1053/berh.2000.0129 Deal, 2012, Bone loss in rheumatoid arthritis: systemic, periarticular, and focal, Curr Rheumatol Rep, 14, 231, 10.1007/s11926-012-0253-7 Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 Grazio, 2012, Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study, Rheumatol Int, 32, 2801, 10.1007/s00296-011-2066-9 Furukawa, 2011, Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus, Rheumatol Int, 31, 365, 10.1007/s00296-009-1244-5 Ismail, 2012, Frequency of low bone mineral density in Saudi patients with inflammatory bowel disease, Saudi J Gastroenterol, 18, 201, 10.4103/1319-3767.96458 Braun, 2012, Pathways for bone loss in inflammatory disease, Curr Osteoporos Rep, 10, 101, 10.1007/s11914-012-0104-5 Døhn, 2011, No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study, Ann Rheum Dis, 70, 252, 10.1136/ard.2009.123729 Smolen, 2005, Arthritis Rheum, 52, 1020, 10.1002/art.20982 Suresh, 2010, Recent advances in rheumatoid arthritis, Postgrad Med J, 86, 243, 10.1136/pgmj.2009.090399 Peters, 2012, The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis, Curr Pharm Des, 18, 1502, 10.2174/138161212799504786 Cacciapaglia, 2011, Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues, Autoimmun Rev, 10, 631, 10.1016/j.autrev.2011.04.014 Haugeberg, 2000, Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register, Arthritis Rheum, 43, 522, 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y Lee, 2012, Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis, Int J Rheum Dis, 15, 289, 10.1111/j.1756-185X.2012.01729.x Wright, 2011, Arthritis increases the risk for fractures—results from the Women's Health Initiative, J Rheumatol, 38, 1680, 10.3899/jrheum.101196 Flachenecker, 2012, Autoimmune diseases and rehabilitation, Autoimmun Rev, 11, 219, 10.1016/j.autrev.2011.05.016 Kanis, 2008, FRAX and the assessment of fracture probability in men and women from the UK, Osteoporos Int, 19, 385, 10.1007/s00198-007-0543-5 van Staa, 2006, Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis, Arthritis Rheum, 54, 3104, 10.1002/art.22117 Shibuya, 2002, Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis, Clin Rheumatol, 21, 150, 10.1007/s10067-002-8274-7 Oelzner, 2008, Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis, Rheumatol Int, 28, 1143, 10.1007/s00296-008-0576-x Haugeberg, 2003, Effects of rheumatoid arthritis on bone, Curr Opin Rheumatol, 15, 469, 10.1097/00002281-200307000-00016 Schett, 2006, High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study, Arch Intern Med, 166, 2495, 10.1001/archinte.166.22.2495 Tengstrand, 2002, Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones, J Rheumatol, 29, 2299 Garnero, 2002, Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study, Arthritis Rheum, 46, 2847, 10.1002/art.10616 Güler-Yüksel, 2010, Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis, Arthritis Res Ther, 12, R96, 10.1186/ar3025 Goldring, 2000, Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications, Arthritis Res, 2, 33, 10.1186/ar67 Gough, 1994, Generalised bone loss in patients with early rheumatoid arthritis, Lancet, 344, 23, 10.1016/S0140-6736(94)91049-9 Epis, 2012, Tight control applied to the biological therapy of rheumatoid arthritis, Autoimmun Rev Arron, 2000, Bone versus immune system, Nature, 408, 535, 10.1038/35046196 Del Fattore, 2012, The tight relationship between osteoclasts and the immune system, Inflamm Allergy Drug Targets, 11, 181, 10.2174/187152812800392733 Redlich, 2002, Osteoclasts are essential for TNF-alpha-mediated joint destruction, J Clin Invest, 110, 1419, 10.1172/JCI0215582 Pettit, 2001, TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis, Am J Pathol, 159, 1689, 10.1016/S0002-9440(10)63016-7 Speziani, 2007, Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines, Eur J Immunol, 37, 747, 10.1002/eji.200636534 Brennan, 2008, Evidence that cytokines play a role in rheumatoid arthritis, J Clin Invest, 118, 3537, 10.1172/JCI36389 Nakashima, 2011, Evidence for osteocyte regulation of bone homeostasis through RANKL expression, Nat Med, 17, 1231, 10.1038/nm.2452 Yeo, 2011, Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis, Ann Rheum Dis, 70, 2022, 10.1136/ard.2011.153312 Braun, 2011, Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis, Arthritis Res Ther, 13, 235, 10.1186/ar3380 Geusens, 2012, The role of RANK ligand/osteoprotegerin in rheumatoid arthritis, Ther Adv Musculoskelet Dis, 4, 225, 10.1177/1759720X12438080 Schett, 2009, Osteoimmunology in rheumatic diseases, Arthritis Res Ther, 11, 210, 10.1186/ar2571 Xu, 2012, Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis, Rheumatol Int, 32, 3397, 10.1007/s00296-011-2175-5 Hodge, 2011, M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts, PLoS One, 6, e21462, 10.1371/journal.pone.0021462 Lam, 2000, TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand, J Clin Invest, 106, 1481, 10.1172/JCI11176 Kitaura, 2005, M-CSF mediates TNF-induced inflammatory osteolysis, J Clin Invest, 115, 3418, 10.1172/JCI26132 Tsukasaki, 2011, Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-α, Biochem Biophys Res Commun, 410, 766, 10.1016/j.bbrc.2011.06.048 Walsh, 2010, Bone remodelling in rheumatic disease: a question of balance, Immunol Rev, 233, 301, 10.1111/j.0105-2896.2009.00857.x Glass, 2005, Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation, Dev Cell, 8, 751, 10.1016/j.devcel.2005.02.017 Daoussis, 2011, The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodelling?, Semin Arthritis Rheum, 41, 170, 10.1016/j.semarthrit.2011.01.006 Diarra, 2007, Dickkopf-1 is a master regulator of joint remodeling, Nat Med, 13, 156, 10.1038/nm1538 Wang, 2011, Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis, J Rheumatol, 38, 821, 10.3899/jrheum.100089 Liu, 2010, Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis, Chin Med J (Engl), 123, 1407 Polzer, 2010, Interleukin-1 is essential for systemic inflammatory bone loss, Ann Rheum Dis, 69, 284, 10.1136/ard.2008.104786 Nakamura, 2006, Regulation of osteoclast differentiation and function by interleukin-1, Vitam Horm, 74, 357, 10.1016/S0083-6729(06)74015-8 De Benedetti, 2006, Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system, Arthritis Rheum, 54, 3551, 10.1002/art.22175 Cheung, 2012, Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression, Bone, 50, 104, 10.1016/j.bone.2011.09.052 Oelzner, 2012, The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis, Rheumatol Int, 32, 199, 10.1007/s00296-010-1606-z Dolan, 2002, Does active treatment of rheumatoidarthritis limit disease-associated bone loss?, Rheumatology (Oxford), 41, 1047, 10.1093/rheumatology/41.9.1047 Van Staa, 2003, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, Arthritis Rheum, 48, 3224, 10.1002/art.11283 Engvall, 2008, Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study, Arthritis Res Ther, 10, R128, 10.1186/ar2542 Haugeberg, 2005, Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial, Arch Intern Med, 165, 1293, 10.1001/archinte.165.11.1293 Wijbrandts, 2009, Bone mineral density in rheumatoid arthritis patients 1year after adalimumab therapy: arrest of bone loss, Ann Rheum Dis, 68, 373, 10.1136/ard.2008.091611 Marotte, 2007, A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab, Arthritis Res Ther, 9, R61, 10.1186/ar2219 Ghazi, 2012, Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids, Osteoporos Int, 23, 581, 10.1007/s00198-011-1584-3 Vestergaard, 2008, Skeletal effects of drugs to treat cancer, Curr Drug Saf, 3, 173, 10.2174/157488608785699522 Minaur, 2002, Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density, Rheumatology (Oxford), 41, 741, 10.1093/rheumatology/41.7.741 Cranney, 2001, The effect of low dose methotrexate on bone density, J Rheumatol, 28, 2395 di Munno, 2004, Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study, J Rheumatol, 31, 1305 Buckley, 1997, Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis, J Rheumatol, 24, 1489 Dílek, 2002, The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis, Yonsei Med J, 43, 435, 10.3349/ymj.2002.43.4.435 Marotte, 2008, Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy, Biologics, 2, 663 Confavreux, 2011, Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis, Osteoporos Int, 22, 1023, 10.1007/s00198-010-1462-4 Ammann, 1997, Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency, J Clin Invest, 99, 1699, 10.1172/JCI119333 D'Amelio, 2008, Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis, Bone, 43, 92, 10.1016/j.bone.2008.02.017 Saidenberg-Kermanac'h, 2004, TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis, Bone, 35, 1200, 10.1016/j.bone.2004.07.004 Kim, 2012, Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study, J Bone Miner Res, 27, 789, 10.1002/jbmr.1489 Kawai, 2012, Initiation of tumor necrosis factor alpha (TNFα) antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases, Arthritis Care Res (Hoboken) Vis, 2003, Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab, Arthritis Rheum, 48, 2996, 10.1002/art.11292 Vis, 2006, Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis, Ann Rheum Dis, 65, 1495, 10.1136/ard.2005.044198 González-Alvaro, 2007, Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists, Ann Rheum Dis, 66, 1675, 10.1136/ard.2007.071910 Ziolkowska, 2002, High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment, Arthritis Rheum, 46, 1744, 10.1002/art.10388 Chopin, 2008, Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis, Ann Rheum Dis, 67, 353, 10.1136/ard.2007.076604 Lange, 2005, Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study, Rheumatology (Oxford), 44, 1546, 10.1093/rheumatology/kei082 Torikai, 2006, The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis, Rheumatology (Oxford), 45, 761, 10.1093/rheumatology/kei280 Yasunori, 2008, Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis, Clin Rheumatol, 27, 1093, 10.1007/s10067-008-0870-8 Daoussis, 2010, Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis, Arthritis Rheum, 62, 150, 10.1002/art.27231 Catrina, 2006, Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis, Arthritis Rheum, 54, 76, 10.1002/art.21528 Vis, 2005, Bone mineral density in patients with rheumatoid arthritis treated with infliximab, Ann Rheum Dis, 64, 336, 10.1136/ard.2003.017780 Seriolo, 2006, Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis, Ann N Y Acad Sci, 1069, 420, 10.1196/annals.1351.040 Gengenbacher, 2008, Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis, Ann Rheum Dis, 67, 620, 10.1136/ard.2007.076711 Güler-Yüksel, 2008, Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis, Ann Rheum Dis, 67, 823, 10.1136/ard.2007.073817 Eekman, 2011, Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis, Ann Rheum Dis, 70, 389, 10.1136/ard.2009.127787 Hoff, 2009, Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study, Ann Rheum Dis, 68, 1171, 10.1136/ard.2008.091264 Krieckaert, 2013, Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study, Rheumatology (Oxford), 52, 547, 10.1093/rheumatology/kes320 Hoff, 2011, Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study, BMC Musculoskelet Disord, 12, 54, 10.1186/1471-2474-12-54 Brown, 2006, Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression, Arthritis Rheum, 54, 3761, 10.1002/art.22190 Plushner, 2008, Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis, Ann Pharmacother, 42, 1660, 10.1345/aph.1L268 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis, 66, 1162, 10.1136/ard.2006.068064 Axmann, 2009, Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo, Arthritis Rheum, 60, 2747, 10.1002/art.24781 Abdel Meguid, 2013, Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage, Rheumatol Int, 33, 697, 10.1007/s00296-012-2375-7 Garnero, 2010, Arthritis Rheum, 62, 33, 10.1002/art.25053 Kanbe, 2012, Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis, Rheumatol Int, 32, 2669, 10.1007/s00296-011-2021-9 Terpos, 2011, Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis, Clin Exp Rheumatol, 29, 921 Buch, 2012, To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 or ACR50, Autoimmun Rev, 11, 558, 10.1016/j.autrev.2011.10.012 Atzeni, 2012, Immunogenicity and autoimmunity during anti-TNF therapy, Autoimmun Rev Nakken, 2011, B-cells and their targeting in rheumatoid arthritis—current concepts and future perspectives, Autoimmun Rev, 11, 28, 10.1016/j.autrev.2011.06.010 Boumans, 2012, Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis, Ann Rheum Dis, 71, 108, 10.1136/annrheumdis-2011-200198 Hein, 2011, Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study, Rheumatol Int, 31, 269, 10.1007/s00296-010-1560-9 Salvin, 2010, Variations in lumbar spine and femoral BMD after rituximab therapy in active rheumatoid arthritis, Ann Rheum Dis, 69, 704 Onal, 2012, Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss, J Biol Chem, 287, 29851, 10.1074/jbc.M112.377945 Yeo, 2010, Analysis of cytokine mRNA profiles of sorted RA synovial fluid cell populations reveal B cells as a major source of RANKL, Ann Rheum Dis, 69, 334 Köller, 2007, Abatacept: the evidence for its place in the treatment of rheumatoid arthritis, Core Evid, 2, 163 Axmann, 2008, CTLA-4 directly inhibits osteoclast formation, Ann Rheum Dis, 67, 1603, 10.1136/ard.2007.080713 Cutolo, 2013, Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis, Autoimmun Rev, 10.1016/j.autrev.2013.01.001 Bedi, 2010, Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss, Ann N Y Acad Sci, 1192, 215, 10.1111/j.1749-6632.2009.05216.x Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493 Deodhar, 2010, Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients, Arthritis Care Res (Hoboken), 62, 569, 10.1002/acr.20004 Sharp, 2010, Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis, Arthritis Care Res (Hoboken), 62, 537, 10.1002/acr.20172 Dore, 2010, Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates, Ann Rheum Dis, 69, 872, 10.1136/ard.2009.112920